For millions of older Americans, the slow erasure of central vision by macular degeneration has long been an irreversible sentence — treatable only in its pace, never its direction. Over a decade of rigorous federal research has now confirmed that a refined supplement formula, replacing a risky compound with two retinal antioxidants, not only slows the disease more effectively but does so without endangering the lives of those who smoke. It is a rare convergence in medicine: a safer path that is also the better one.
NIH Study Confirms Lutein-Zeaxanthin Formula Slows AMD Progression Better Than Beta-Carotene
AMD is the most common cause of blindness in older Americans; the study demonstrates how safer supplements can prevent vision loss.
The new formula works better and harms no one
Mark
So this is about finding a better vitamin formula for people losing their sight. What made them change the original recipe?
Mimi
Beta-carotene worked—it slowed macular degeneration. But it turned out smokers who took it had nearly double the lung cancer risk. That was discovered in the original AREDS study itself.
Luke
Wait—so they knew about the lung cancer problem in the 1990s, but it took until 2006 to launch a replacement study?
Mimi
Yes. They needed time to identify alternatives and design a new trial. Lutein and zeaxanthin are also antioxidants that work in the retina, so they were logical candidates.
Mark
And the new formula actually works better?
Mimi
After ten years, yes. The lutein-zeaxanthin group had 20 percent additional protection against progression to late AMD compared to the beta-carotene group.
Luke
But everyone switched to the new formula after the initial five-year study ended, right? So how do they know the ten-year difference wasn't just from people staying on the better formula longer?
Mimi
They tracked which group people were originally assigned to, even after everyone switched. The original assignment still predicted outcomes a decade later.
Mark
So it's safe for smokers now?
Mimi
The lutein-zeaxanthin formula showed no increased lung cancer risk, even in people with a smoking history.
Luke
And that's based on 3,883 people followed for ten years total. Not a small sample, but not enormous either.
Mark
Does this mean everyone with AMD should take this supplement?
Mimi
The study shows it slows progression. It's not a cure, and it works best in moderate disease. But for people at risk, it's a proven way to preserve vision longer.
Il Polso
- Age-related macular degeneration is the leading cause of blindness in older Americans, and it advances without cure — making any intervention that slows it a matter of profound consequence.
- The original NIH supplement formula contained beta-carotene, which was later found to nearly double lung cancer risk in smokers, creating a dangerous trade-off between protecting sight and threatening life.
- In 2006, researchers redesigned the formula, substituting lutein and zeaxanthin — antioxidants naturally active in the retina — and restricted the old beta-carotene version to non-smokers only.
- A decade-long follow-up of nearly 3,900 participants confirmed the new formula reduces AMD progression risk by 26%, with an additional 20% advantage over beta-carotene after ten years.
- The findings now support universal adoption of the safer formula across all populations, including current smokers, resolving the conflict between efficacy and safety that had shadowed the original study.
For millions of older Americans, the slow erasure of central vision by macular degeneration has long been an irreversible sentence — treatable only in its pace, never its direction. Over a decade of rigorous federal research has now confirmed that a refined supplement formula, replacing a risky compound with two retinal antioxidants, not only slows the disease more effectively but does so without endangering the lives of those who smoke. It is a rare convergence in medicine: a safer path that is also the better one.
Age-related macular degeneration destroys the cells responsible for sharp central vision, and it is the leading cause of blindness among older Americans. There is no cure — only the possibility of slowing its advance. That possibility has been the subject of federal research for nearly three decades.
In 1996, the National Institutes of Health launched the original Age-Related Eye Disease Study, testing a vitamin formula that included beta-carotene alongside vitamin C, vitamin E, zinc, and copper. The formula worked: it meaningfully slowed progression from moderate to late-stage disease. But a shadow fell over the results when concurrent NIH studies found that beta-carotene significantly elevated lung cancer risk in smokers.
The safety concern prompted a redesign. In 2006, researcher Emily Chew of the National Eye Institute led AREDS2, replacing beta-carotene with 10 milligrams of lutein and 2 milligrams of zeaxanthin — antioxidants that, like beta-carotene, are active in the retina. The original formula was offered only to participants who had never smoked or had already quit. After five years, the new formula showed no lung cancer risk and reduced AMD progression by roughly 26 percent.
A decade-long follow-up, now published in JAMA Ophthalmology, tracked nearly 3,900 of the original participants for five additional years. The conclusions were unambiguous: beta-carotene nearly doubled lung cancer risk among ever-smokers, while the lutein-zeaxanthin group showed none. After a full decade, those originally assigned the new formula had an additional 20 percent reduced risk of late AMD compared to those who had received beta-carotene.
The research resolves what had been a genuine ethical tension in preventive medicine — the need to choose between a treatment that works and one that is safe. Here, the safer option proved to be the more effective one as well, opening the door to its use across all populations, smokers included.
Age-related macular degeneration steals vision gradually and irreversibly. The disease kills cells in the macula, the part of the retina responsible for sharp central sight, and it is the leading cause of blindness among older Americans. There is no cure. But for nearly three decades, researchers have known that certain dietary supplements can slow its advance.
In 1996, the National Institutes of Health launched the Age-Related Eye Disease Study, or AREDS, to test whether a specific vitamin formula could help. The original combination included 500 milligrams of vitamin C, 400 international units of vitamin E, 80 milligrams of zinc, 2 milligrams of copper, and 15 milligrams of beta-carotene. The results were clear: people who took it experienced significantly slower progression from moderate to late-stage disease. But the same research revealed a troubling trade-off. Two concurrent NIH-supported studies found that smokers who took beta-carotene faced a substantially elevated risk of lung cancer.
This safety problem prompted a redesign. In 2006, researchers led by Emily Chew, director of the Division of Epidemiology and Clinical Application at the National Eye Institute, launched AREDS2. The new formula swapped out beta-carotene for two other antioxidants: 10 milligrams of lutein and 2 milligrams of zeaxanthin. Both compounds are active in the retina, just as beta-carotene is. The original beta-carotene formula was offered only to study participants who had never smoked or had already quit.
After five years, the results justified the switch. Lutein and zeaxanthin carried no increased lung cancer risk. More importantly, the new formula reduced the risk of AMD progression by approximately 26 percent. When the initial study period ended in 2011, all participants were offered the updated formula containing lutein and zeaxanthin.
Now, a decade-long follow-up published in JAMA Ophthalmology extends the picture. Researchers tracked 3,883 of the original 4,203 AREDS2 participants for another five years after the study's conclusion, monitoring whether their AMD had advanced to late disease and whether they had developed lung cancer. The findings reinforced the earlier conclusions with added force. Among people who had ever smoked, beta-carotene nearly doubled the risk of lung cancer. The lutein-zeaxanthin group showed no such increase. And after a full decade, those originally assigned to lutein and zeaxanthin had an additional 20 percent reduced risk of progression to late AMD compared to those who had received beta-carotene.
Chew described the outcome as confirmation that the formula change was correct. The study demonstrates something more: a supplement that works better and harms no one, regardless of smoking history. For millions of older Americans facing the prospect of vision loss, the distinction matters. The research shows that prevention is possible, that the right intervention can slow a disease that has no cure, and that safety and efficacy need not be in conflict.
Citazioni salienti
These results confirmed that switching our formula from beta-carotene to lutein and zeaxanthin was the right choice.— Emily Chew, M.D., director of the Division of Epidemiology and Clinical Application at the National Eye Institute
Vuoi la storia completa?
Leggi l'originale su News-Medical.net ↗
Health & Medicine